Jeremy P. Segal
YOU?
Author Swipe
View article: A Molecular Dissection of the Ventromedial Hypothalamic Nucleus
A Molecular Dissection of the Ventromedial Hypothalamic Nucleus Open
The ventromedial hypothalamic nucleus (VMH) plays an important role in the regulation of food intake, glucose metabolism, and body weight. However, in contrast to other hypothalamic nuclei that are also known to regulate energy homeostasis…
View article: Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults Open
TP53-mutant acute lymphoblastic leukemia (ALL) in adults is a high-risk subtype with poor outcomes, yet its molecular landscape and clinical implications remain incompletely defined. In this multi-institutional study of 830 adult ALL patie…
View article: Corrigendum to “Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist” [Modern Pathology 38 (2025) 100752]
Corrigendum to “Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist” [Modern Pathology 38 (2025) 100752] Open
View article: Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report
Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report Open
View article: Sequential tumor molecular profiling identifies likely germline variants
Sequential tumor molecular profiling identifies likely germline variants Open
View article: A novel telomere biology disease‐associated gastritis identified through a whole exome sequencing‐driven approach
A novel telomere biology disease‐associated gastritis identified through a whole exome sequencing‐driven approach Open
A whole exome sequencing (WES)‐driven approach to uncover the etiology of unexplained inflammatory gastritides has been underutilized by surgical pathologists. Here, we discovered the pathobiology of an unusual chronic atrophic gastritis i…
View article: The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology
The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology Open
Innovative and self-sustaining clinical genomics laboratories specializing in cutting-edge oncology testing are critical to the success of academic pathology departments and resident and fellow education in molecular pathology. However, th…
View article: Data from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Data from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies Open
Purpose:Preclinical studies suggest SYK and JAK contribute to tumor-intrinsic and microenvironment-derived survival signals. The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investig…
View article: Supplementary Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Supplementary Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma Open
Supplemental Figures 1 and 2 (S1. Measurement of autophagic vesicles in PBMC and S2 Massively parallel sequencing and outcome.
View article: Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5…
View article: Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
Include supplementary Figure S1-S4 legends; Supplementary Table S1 and S4; and list Supplementary Table S2 and S3 titles. Supplementary Table S1. The panel of drugs used in vitro and in vivo with their doses and duration. Supplementary Tab…
View article: Supplementary Table S2 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Table S2 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Germline BRCA1/2 Mutations and Variant Allele Frequencies detected in the FFPE-isolated tumor DNA
View article: Supplementary Fig. S4 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Fig. S4 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
CD8-positive T-cell infiltrate stratified by loss of heterozygosity status.
View article: Supplementary Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Supplementary Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma Open
Supplemental Figures 1 and 2 (S1. Measurement of autophagic vesicles in PBMC and S2 Massively parallel sequencing and outcome.
View article: Supplementary Data (Table S1, Figure S1, Figure S2, Figure S3) from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Supplementary Data (Table S1, Figure S1, Figure S2, Figure S3) from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies Open
Supplemental Appendix (Table S1, Figure S1, Figure S2, Figure S3)
View article: Supplementary Table S2. The RPPA antibody list from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Table S2. The RPPA antibody list from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
Supplementary Table S2. The RPPA antibody list
View article: Supplementary Table S1 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Table S1 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Clinicopathologic characteristics of the complete cohort
View article: Supplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
Supplementary Table S3. OncoPlus Gene List and Identified Variants
View article: Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for …
View article: Supplementary Fig. S3 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Fig. S3 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Examples of morphological characteristics associated with gBRCA/LOHpos ECs.
View article: Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for …
View article: Data from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Data from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies Open
Purpose:Preclinical studies suggest SYK and JAK contribute to tumor-intrinsic and microenvironment-derived survival signals. The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investig…
View article: Supplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
Supplementary Table S3. OncoPlus Gene List and Identified Variants
View article: Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy Open
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5…
View article: Supplementary Fig. S3 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Fig. S3 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Examples of morphological characteristics associated with gBRCA/LOHpos ECs.
View article: Data from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Data from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Purpose:Whether endometrial carcinoma (EC) should be considered part of the gBRCA1/2-associated hereditary breast and ovarian cancer (HBOC) syndrome is topic of debate. We sought to assess whether ECs occurring in gBRCA carri…
View article: Supplementary Fig. S2 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Fig. S2 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Overall survival of women with gBRCA/LOHpos ECs (n=24) and gBRCA/LOHneg ECs (n=16).
View article: Supplementary Fig. S2 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Supplementary Fig. S2 from Germline <i>BRCA</i>-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Open
Overall survival of women with gBRCA/LOHpos ECs (n=24) and gBRCA/LOHneg ECs (n=16).
View article: Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma Open
Purpose:Everolimus inhibits the mTOR, activating cytoprotective autophagy. Hydroxychloroquine inhibits autophagy. On the basis of preclinical data demonstrating synergistic cytotoxicity when mTOR inhibitors are combined with an autophagy i…
View article: Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Data from Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma Open
Purpose:Everolimus inhibits the mTOR, activating cytoprotective autophagy. Hydroxychloroquine inhibits autophagy. On the basis of preclinical data demonstrating synergistic cytotoxicity when mTOR inhibitors are combined with an autophagy i…